Skip to content
Inciteful Med

Welcome and Orientation: Understanding ADOA

Last updated:

Autosomal Dominant Optic Atrophy (ADOA) is a slow-progressing genetic condition affecting the optic nerve. While it can lead to central vision loss, total blindness is extremely rare. Most patients retain their peripheral vision, allowing them to navigate safely and maintain independence.

Key Takeaways

  • • Autosomal Dominant Optic Atrophy (ADOA) is a genetic mitochondrial condition that affects the optic nerve.
  • • Vision changes in ADOA usually begin in early childhood and progress very slowly over time.
  • • While ADOA can cause the loss of fine central vision, total blindness is extremely rare.
  • • Peripheral vision typically remains intact, enabling patients to maintain their independence and navigate safely.
  • • ADOA is the most common hereditary optic neuropathy but is often misdiagnosed as lazy eye or glaucoma in its early stages.

Receiving a diagnosis of Autosomal Dominant Optic Atrophy (ADOA)—sometimes called Kjer-type optic atrophy—often brings a wave of fear and uncertainty. It is natural to feel overwhelmed, but it is important to know that you are now in a position to find the right care.

ADOA is a genetic mitochondrial condition, meaning it affects the “power plants” of the cells [1][2]. Specifically, it affects the optic nerve, which is the cable that carries visual information from the eye to the brain [3][4].

Three Stabilizing Facts

While a diagnosis of a “progressive” condition is daunting, the clinical reality of ADOA is often more manageable than patients first fear:

  1. Slow Progression: Unlike some other vision conditions that cause rapid decline, ADOA is typically very slow-moving [4][5]. Vision changes often begin in early childhood and may remain stable for long periods [4][6].
  2. Preservation of Independence: Many patients fear that “progressive” means total darkness. While many people with ADOA may eventually meet the criteria for legal blindness, this specifically means losing the ability to see fine central detail (like small text or recognizing faces from afar) [4][7]. Crucially, the peripheral (side) vision remains intact, allowing patients to walk around independently and navigate their environment safely [8][9]. Total blindness (having no light perception) is extremely rare in ADOA.
  3. Protected Vision Cells: Research shows that certain specialized light-sensing cells in the retina (called ipRGCs) appear to be protected from the damage that affects other cells in ADOA [10][11]. This unique biological “shield” may help explain why some aspects of light perception remain intact.

Understanding Prevalence and Incidence

ADOA is recognized as the most common form of hereditary optic neuropathy (inherited nerve damage in the eye) [1][5]. It is estimated to affect between 1 in 12,000 and 1 in 25,000 people [12][13]. Because the condition is often mild in its early stages, doctors believe it may be underdiagnosed or sometimes mistaken for other conditions like “lazy eye” or glaucoma [14][15].

Navigating This Guide

To help you and your family understand this diagnosis and take proactive steps, we have broken down the critical information into the following sections:

Frequently Asked Questions

What is Autosomal Dominant Optic Atrophy (ADOA)?
ADOA is an inherited condition that affects the optic nerve, which is the cable carrying visual information from your eye to your brain. It is considered a mitochondrial disorder because it affects the energy-producing centers of your cells.
Will ADOA cause me to go completely blind?
Total blindness, meaning zero light perception, is extremely rare in ADOA. The condition primarily affects fine central vision, which can lead to legal blindness. However, patients typically keep their peripheral, or side vision, allowing them to remain mobile and independent.
How fast does vision loss progress in ADOA?
ADOA is typically a very slow-moving condition. Vision changes often begin in early childhood and may remain stable for long stretches of time, unlike some other eye conditions that cause rapid vision decline.
Why do I need an OCT scan for ADOA?
Optical Coherence Tomography (OCT) is a non-invasive imaging test that creates cross-sectional pictures of your retina and optic nerve. Your neuro-ophthalmologist uses baseline and follow-up OCT scans to monitor the health of your optic nerve and track any disease progression over time.

Questions for Your Doctor

  • • What is the specific genetic mutation in my (or my child’s) case, and does it typically follow the 'classic' or 'plus' course?
  • • Can you refer us to a neuro-ophthalmologist who has experience managing ADOA?
  • • What are the results of the baseline OCT (Optical Coherence Tomography) and how often should we repeat this imaging?

Questions for You

  • • When did you first notice changes in vision, and have those changes stayed the same or worsened over time?
  • • Does anyone else in the family have a history of 'lazy eye,' early-onset vision loss, or unexplained hearing issues?
  • • What are your primary goals for daily life (e.g., reading, driving, school support) that we should prioritize during monitoring?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy.

    Ding C, Ndiaye PS, Campbell SR, et al.

    The Journal of clinical investigation 2025; (135(12)).

    PMID: 40344041
  2. 2

    Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy.

    Ahuja AS, Selvam P, Vadlamudi C, et al.

    Ophthalmic genetics 2020; (41(6)):563-569 doi:10.1080/13816810.2020.1814344.

    PMID: 32940104
  3. 3

    Exome sequencing identified a novel de novo OPA1 mutation in a consanguineous family presenting with optic atrophy.

    Cohen L, Tzur S, Goldenberg-Cohen N, et al.

    Genetics research 2016; (98()):e10 doi:10.1017/S0016672316000070.

    PMID: 27265430
  4. 4

    [Hereditary Optic Neuropathies].

    Rüther K

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(6)):747-763 doi:10.1055/a-0583-6290.

    PMID: 29490390
  5. 5

    Mitochondrial optic neuropathies.

    Carelli V, La Morgia C, Yu-Wai-Man P

    Handbook of clinical neurology 2023; (194()):23-42 doi:10.1016/B978-0-12-821751-1.00010-5.

    PMID: 36813316
  6. 6

    Mitochondrial disorders of the retinal ganglion cells and the optic nerve.

    Finsterer J, Mancuso M, Pareyson D, et al.

    Mitochondrion 2018; (42()):1-10 doi:10.1016/j.mito.2017.10.003.

    PMID: 29054473
  7. 7

    Induced Pluripotent Stem Cells for Inherited Optic Neuropathies-Disease Modeling and Therapeutic Development.

    Harvey JP, Sladen PE, Yu-Wai-Man P, Cheetham ME

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2022; (42(1)):35-44 doi:10.1097/WNO.0000000000001375.

    PMID: 34629400
  8. 8

    "Adrift From the World": Exploring the Lived Experiences of Individuals Affected by an Inherited Optic Neuropathy in the United Kingdom-A Qualitative Study.

    Chen BS, Seikus C, Ferguson J, et al.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2025; doi:10.1016/j.jval.2025.07.023.

    PMID: 40774594
  9. 9

    Vision-related quality of life and visual ability in patients with autosomal dominant optic atrophy.

    Eckmann-Hansen C, Bek T, Sander B, Larsen M

    Acta ophthalmologica 2022; (100(7)):797-804 doi:10.1111/aos.15102.

    PMID: 35146926
  10. 10

    Pupillometric evaluation of the melanopsin containing retinal ganglion cells in mitochondrial and non-mitochondrial optic neuropathies.

    Ba-Ali S, Lund-Andersen H

    Mitochondrion 2017; (36()):124-129 doi:10.1016/j.mito.2017.07.003.

    PMID: 28716667
  11. 11

    Influence of Opa1 Mutation on Survival and Function of Retinal Ganglion Cells.

    González-Menéndez I, Reinhard K, Tolivia J, et al.

    Investigative ophthalmology & visual science 2015; (56(8)):4835-45 doi:10.1167/iovs.15-16743.

    PMID: 26218912
  12. 12

    ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy.

    Caporali L, Magri S, Legati A, et al.

    Annals of neurology 2020; (88(1)):18-32 doi:10.1002/ana.25723.

    PMID: 32219868
  13. 13

    [Genetic Causes and Genetic Diagnostic Testing of Inherited Optic Atrophies].

    Wissinger B

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(11)):1235-1241 doi:10.1055/a-0759-2094.

    PMID: 30458563
  14. 14

    [Differential diagnosis of juvenile normal pressure glaucoma].

    Geidel K, Wiedemann P, Unterlauft JD

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2017; (114(9)):828-831 doi:10.1007/s00347-016-0407-5.

    PMID: 27921132
  15. 15

    Novel truncating mutation in CACNA1F in a young male patient diagnosed with optic atrophy.

    Pasutto F, Ekici A, Reis A, et al.

    Ophthalmic genetics 2018; (39(6)):741-748 doi:10.1080/13816810.2018.1520263.

    PMID: 30260717

This overview of Autosomal Dominant Optic Atrophy is for informational purposes only. Always consult a neuro-ophthalmologist or genetic counselor regarding your specific diagnosis, genetic mutation, and symptom management.

Stay up to date

Get notified when new research about Autosomal dominant optic atrophy, classic form is published.

No spam. Unsubscribe anytime.